It has been shown that SGLT2 inhibitors combined with an angiotensin-converting enzyme inhibitor upregulate the renin–angiotensin system effect in nephropathy, therefore suggesting that blood pressure changes may be influenced by SGLT2 inhibitors (7, 8). The gene discussed is SLC5A2; the disease is kidney disorder.